CuraGen Begins Clinical Testing of Skin Cancer Drug
Posted on: Friday, 23 June 2006, 09:00 CDT
After receiving approval from the FDA to begin human trials, CuraGen Corporation has begun dosing patients with a monoclonal antibody-drug conjugate in a phase I clinical trial in metastatic melanoma, a deadly form of skin cancer.
The open-label, multi-center, dose-escalation study will evaluate the safety, tolerability and pharmacokinetics of the antibody, CR011-vcMMAE, for patients with unresectable stage III or stage IV melanoma who have failed no more than one prior line of cytotoxic therapy. CuraGen anticipates preliminary results from this phase I trial will be available in the fourth quarter of 2007.
The first part of the trial will evaluate cohorts of patients receiving increasing doses of the antibody to determine the maximum tolerated dose (MTD). After determination of the MTD, up to approximately 30 additional patients will be enrolled and treated at the MTD to further define safety and efficacy in this phase I trial.
"We believe the disease specificity and targeted nature of CR011-vcMMAE will accelerate the evaluation of this therapeutic in the clinic, where we hope to replicate the activity we saw with this agent in preclinical studies," stated Dr Frank Armstrong, president and CEO of CuraGen.
Source: Datamonitor
Related Articles
- Altus Pharmaceuticals Reports Last Patient Visit Of Trizytek(TM) Phase 3 Efficacy Trial
- DiaMedica Announces Last Patient Out for DM-83 Phase II Human Clinical Trial
- Pro-Pharmaceuticals Announces Tampa General Hospital Dosing Patients With DAVANAT(R)/5-FU in Phase II, First Line, Advanced Biliary Cancer Clinical Trial
- Nuvelo Announces Completion of Patient Enrollment in NAPA-2, First Phase 3 Trial of Alfimeprase in Acute Peripheral Arterial Occlusion
- Nuvelo Announces Completion of Patient Enrollment in SONOMA-2, First Phase 3 Trial of Alfimeprase in Central Venous Catheter Occlusion
- LAB International Initiates Patient Enrollment for LAB-CGRP Phase IIa Trial
- Oncolytics Biotech Inc. Announces Conclusion of Patient Follow Up in Canadian Phase I Recurrent Malignant Glioma Clinical Trial
- First Patient Enrolled in Investigator-Sponsored Phase 1/2 Trial of Antigenics' Oncophage Cancer Vaccine in Glioma
- Pro-Pharmaceuticals Announces Dosing of Patient With DAVANAT(R)/5-FU in Phase II Colorectal Cancer Trial at Ochsner Cancer Institute
- Pro-Pharmaceuticals Announces Dosing of Cancer Patient With DAVANAT/5-FU in a Phase II Clinical Trial at Medical Oncology & Hematology, P.C.
 |
 |
User Comments (0)
RSS Feeds